Lumos Pharma — Company Overview, News & Financial Data
Lumos Pharma specializes in therapies for rare diseases, focusing on treatments for growth disorders.
About Lumos Pharma
Lumos Pharma (NASDAQ:LUMO) specializes in developing innovative therapies for rare diseases with a primary focus on growth disorders. Aiming to significantly improve patients' lives, their flagship project revolves around a novel treatment for Pediatric Growth Hormone Deficiency, showcasing their commitment to addressing unmet medical needs in the rare disease community. Lumos Pharma operates with the objective to leverage cutting-edge science for creating breakthrough treatments that can lead to better health outcomes for those affected by rare and neglected conditions.
Snapshot
Operations
Products and/or services of Lumos Pharma
- Development of LUM-201, oral therapy aimed at pediatric growth hormone deficiency.
- Researching treatments for rare diseases with a focus on endocrine disorders.
- Advancement of therapies targeting genetic disorders leading to growth deficiencies.
- Collaboration with academic and medical institutions for clinical trials on novel therapeutics.
- Provision of comprehensive support services for patients and healthcare professionals involved in their trials.
- Investment in cutting-edge biopharmaceutical research to explore innovative treatment options.
Lumos Pharma executive team
- Mr. Richard J. HawkinsFounder, CEO & Chairman
- Dr. John C. McKew Ph.D.Chief Scientific Officer & President
- Ms. Lori D. Lawley CPACFO & Principal Accounting Officer
- Ms. Lisa Wells MillerSenior Director of Investor Relations
- Mr. Bradley J. Powers J.D.Chief Compliance Officer & General Counsel
- Mr. Aaron Schuchart B.B.A., CPA, M.B.A.Chief Business Officer
- Dr. Pisit Pitukcheewanont FAAP, M.D.Chief Medical Officer
- Ms. Alpa ParikhSenior Vice President of CMC & Supply Management
- Mr. Eddie L. Varnado M.B.A.Corporate Controller
GET YOUR GRAFA EDGE NOW
We'll switch on a 30-day Edge trial as a welcome gift